"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 6 | 0 | 6 |
| 2015 | 5 | 2 | 7 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 1 | 5 |
| 2018 | 8 | 1 | 9 |
| 2019 | 7 | 2 | 9 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 7 | 0 | 7 |
| 2023 | 1 | 0 | 1 |
| 2024 | 6 | 2 | 8 |
| 2025 | 2 | 1 | 3 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs. Cancer Prev Res (Phila). 2026 02 06; 19(2):79-92.
-
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial. JAMA. 2026 Feb 03; 335(5):407-415.
-
Association of Metformin Use and New-Onset International Classification of Diseases Coding of Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2026 Jun; 10(6):642-650.
-
Association Between Metformin and Other Diabetic Medications and Five-year Onset of New Neovascular Age-related Macular Degeneration Diagnosis. Ophthalmic Surg Lasers Imaging Retina. 2026 Feb; 57(2):102-111.
-
Structural basis of drug recognition by human MATE1 transporter. Nat Commun. 2025 Oct 27; 16(1):9444.
-
The 2018 World Cancer Research Fund/American Institute for Cancer Research Score and Cancer Risk: results from the diabetes prevention program outcomes study. Am J Clin Nutr. 2025 Sep; 122(3):715-723.
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 03; 194:18-24.
-
Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. Int J Mol Sci. 2024 Oct 22; 25(21).
-
Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population. Diabetes Obes Metab. 2024 11; 26(11):5261-5271.
-
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease. AAPS J. 2024 08 19; 26(5):94.